Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

References

• LiyanageKEBurnettJRHooperAJvan BockxmeerFMFamilial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distributionCrit Rev Clin Lab Sci201148111821657943
   PubMed Web of Science ®Google Scholar
• MüllerCXanthomata, hypercholesterolemia, angina pectorisActa Med Scand19388975
   Google Scholar
• KhachadurianAKThe inheritance of essential familial hypercholesterolemiaAm J Med19643740240714209286
   PubMed Web of Science ®Google Scholar
• BrownMSKovanenPTGoldsteinJLRegulation of plasma cholesterol by lipoprotein receptorsScience198121244956286356261329
   PubMed Web of Science ®Google Scholar
• GoldsteinJLBrownMSThe LDL receptorArterioscler Thromb Vasc Biol200929443143819299327
   PubMed Web of Science ®Google Scholar
• BrownMSGoldsteinJLA receptor-mediated pathway for cholesterol homeostasisScience1986232474634473513311
   PubMed Web of Science ®Google Scholar
• BilheimerDWStoneNJGrundySMMetabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivoJ Clin Invest1979642524533222811
   PubMed Web of Science ®Google Scholar
• CummingsMHWattsGFUmplebyMHennessyTRQuineyJRSonksenPHIncreased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope studyAtherosclerosis1995113179897755658
   PubMed Web of Science ®Google Scholar
• MillarJSMaugeaisCIkewakiKComplete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 productionArterioscler Thromb Vasc Biol200525356056515637307
   PubMed Web of Science ®Google Scholar
• TremblayAJLamarcheBRuelILIncreased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutationJ Lipid Res200445586687214967814
   PubMed Web of Science ®Google Scholar
• FaizFHooperAJvan BockxmeerFMMolecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statinsCrit Rev Clin Lab Sci201249111722214202
   PubMed Web of Science ®Google Scholar
• SoutarAKNaoumovaRPMechanisms of disease: genetic causes of familial hypercholesterolemiaNat Clin Pract Cardiovasc Med20074421422517380167
   PubMedGoogle Scholar
• LeighSEFosterAHWhittallRAHubbartCSHumphriesSEUpdate and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia databaseAnn Hum Genet200872Pt 448549818325082
   PubMed Web of Science ®Google Scholar
• SoriaLFLudwigEHClarkeHRVegaGLGrundySMMcCarthyBJAssociation between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100Proc Natl Acad Sci U S A19898625875912563166
   PubMed Web of Science ®Google Scholar
• SeftelHCBakerSGSandlerMPA host of hypercholesterolaemic homozygotes in South AfricaBMJ198028162416336367437743
   PubMed Web of Science ®Google Scholar
• FahedACSafaRMHaddadFFHomozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlationMol Genet Metab2011102218118821145767
   PubMed Web of Science ®Google Scholar
• MoorjaniSRoyMGagneCHomozygous familial hypercholesterolemia among French Canadians in Quebec ProvinceArteriosclerosis1989922112162923577
   PubMedGoogle Scholar
• SlackJRisks of ischaemic heart-disease in familial hyperlipoproteinaemic statesLancet196927635138013824188273
   PubMed Web of Science ®Google Scholar
• StoneNJLevyRIFredricksonDSVerterJCoronary artery disease in 116 kindred with familial type II hyperlipoproteinemiaCirculation19744934764884813182
   PubMed Web of Science ®Google Scholar
• TonstadSJoakimsenOStensland-BuggeERisk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjectsArterioscler Thromb Vasc Biol19961689849918696963
   PubMed Web of Science ®Google Scholar
• WiegmanAde GrootEHuttenBAArterial intima-media thickness in children heterozygous for familial hypercholesterolaemiaLancet2004363940636937015070569
   PubMed Web of Science ®Google Scholar
• KhachadurianAKUthmanSMExperiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patientsNutr Metab19731511321404351242
   PubMedGoogle Scholar
• SummersRMAndrasko-BourgeoisJFeuersteinIMEvaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemiaCirculation19989865095189714107
   PubMed Web of Science ®Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register GroupBMJ199130368078938961933004
   PubMedGoogle Scholar
• World Health OrganizationFamilial Hypercholesterolaemia (FH)Report of a second WHOT ConsultationGenevaSeptember 4, 1998GenevaWorld Health Organization Human Genetics Programme1999 Available from http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdfAccessed August 1, 2012
   Google Scholar
• WilliamsRRHuntSCSchumacherMCDiagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular geneticsAm J Cardiol19937221711768328379
   PubMed Web of Science ®Google Scholar
• RaalFJSantosRDHomozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatmentAtherosclerosis2012223226226822398274
   PubMed Web of Science ®Google Scholar
• WilsonJMJungnerGPrinciples and Practice of Screening for GiseaseGeneva, SwitzerlandWorld Health Organization1968
   Google Scholar
• BenderRBellDAHooperAJScreening for familial hypercholesterolaemiaPathology201244212212822228254
   PubMed Web of Science ®Google Scholar
• BellDAHooperAJBenderROpportunistic screening for familial hypercholesterolaemia via a community laboratoryAnn Clin Biochem Epub September 21, 2012
   Web of Science ®Google Scholar
• RaalFJPilcherGJPanzVRReduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapyCirculation2011124202202220721986285
   PubMed Web of Science ®Google Scholar
• KasteleinJJAkdimFStroesESSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med2008358141431144318376000
   PubMed Web of Science ®Google Scholar
• ThompsenJThompsonPDA systematic review of LDL apheresis in the treatment of cardiovascular diseaseAtherosclerosis20061891313816546196
   PubMed Web of Science ®Google Scholar
• ThompsonGRLipoprotein apheresisCurr Opin Lipidol201021648749121206339
   PubMed Web of Science ®Google Scholar
• ThompsonGRCatapanoASahebSSevere hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in EuropeCurr Opin Lipidol201021649249820935563
   PubMed Web of Science ®Google Scholar
• MoiniMMistryPSchilskyMLLiver transplantation for inherited metabolic disorders of the liverCurr Opin Organ Transplant201015326927620489626
   PubMed Web of Science ®Google Scholar
• PijlmanAHHuijgenRVerhagenSNEvaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The NetherlandsAtherosclerosis2010209118919419818960
   PubMed Web of Science ®Google Scholar
• AbifadelMVarretMRabesJPMutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat Genet200334215415612730697
   PubMed Web of Science ®Google Scholar
• BennMNordestgaardBGGrandePSchnohrPTybjaerg-HansenAPCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analysesJ Am Coll Cardiol201055252833284220579540
   PubMed Web of Science ®Google Scholar
• CohenJCBoerwinkleEMosleyTHJrHobbsHHSequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN Engl J Med2006354121264127216554528
   PubMed Web of Science ®Google Scholar
• HooperAJMaraisADTanyanyiwaDMBurnettJRThe C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African populationAtherosclerosis2007193244544816989838
   PubMed Web of Science ®Google Scholar
• ZhaoZTuakli-WosornuYLagaceTAMolecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygoteAm J Hum Genet200679351452316909389
   PubMed Web of Science ®Google Scholar
• McKenneyJMKorenMJKereiakesDJHanotinCFerrandACSteinEASafety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/ REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapyJ Am Coll Cardiol201259252344235322463922
   PubMed Web of Science ®Google Scholar
• SteinEAGipeDBergeronJEffect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialLancet2012380293622633824
   PubMed Web of Science ®Google Scholar
• SteinEAMellisSYancopoulosGDEffect of a monoclonal antibody to PCSK9 on LDL cholesterolN Engl J Med2012366121108111822435370
   PubMed Web of Science ®Google Scholar
• HussainMMIqbalJAnwarKRavaPDaiKMicrosomal triglyceride transfer protein: a multifunctional proteinFront Biosci20038500506
   PubMed Web of Science ®Google Scholar
• BurnettJRWattsGFMTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?Expert Opin Ther Targets200711218118917227233
   PubMed Web of Science ®Google Scholar
• HussainMMBakillahANew approaches to target microsomal triglyceride transfer proteinCurr Opin Lipidol200819657257818957879
   PubMed Web of Science ®Google Scholar
• Aegerion Pharmaceuticals: We are Bullish on the Lomitapide Story682012 Available from: http://seekingalpha.com/article/645951-aegerion-pharmaceuticals-we-are-bullish-on-the-lomitapide-storyAccessed October 12, 2012
   Google Scholar
• CuchelMBloedonLTSzaparyPOInhibition of microsomal triglyceride transfer protein in familial hypercholesterolemiaN Engl J Med2007356214815617215532
   PubMed Web of Science ®Google Scholar
• HooperAJBurnettJRDalcetrapib, a cholesteryl ester transfer protein modulatorExpert Opin Invest Drugs201221914271432
   PubMed Web of Science ®Google Scholar
• HooperAJBurnettJRAnacetrapib, a cholesteryl ester transfer protein inhibitorExpert Opin Invest Drugs2012211103109
   PubMed Web of Science ®Google Scholar
• GuerinMReverse cholesterol transport in familial hypercholesterolemiaCurr Opin Lipidol201223437738522510809
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med2007357212109212217984165
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification82012 Available from: http://clinicaltrials.gov/ct2/show/NCT01252953Accessed October 12, 2012
   Google Scholar
• YuRZLemonidisKMGrahamMJCross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100Biochem Pharmacol200977591091919056355
   PubMed Web of Science ®Google Scholar
• YuRZKimTWHongAWatanabeTAGausHJGearyRSCross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100Drug Metab Dispos200735346046817172312
   PubMed Web of Science ®Google Scholar
• YuRZGearyRSFlaimJDLack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibeClin Pharmacokinet2009481395019071883
   PubMed Web of Science ®Google Scholar
• KasteleinJJWedelMKBakerBFPotent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein BCirculation2006114161729173517030687
   PubMed Web of Science ®Google Scholar
• AkdimFVisserMETribbleDLEffect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemiaAm J Cardiol2010105101413141920451687
   PubMed Web of Science ®Google Scholar
• ClarkeRPedenJFHopewellJCGenetic variants associated with Lp(a) lipoprotein level and coronary diseaseN Engl J Med2009361262518252820032323
   PubMed Web of Science ®Google Scholar
• ErqouSKaptogeSPerryPLLipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortalityJAMA2009302441242319622820
   PubMed Web of Science ®Google Scholar
• NenseterMSLindvigHWUelandTLipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemiaAtherosclerosis2011216242643221376325
   PubMed Web of Science ®Google Scholar
• RaalFJSantosRDBlomDJMipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialLancet20103759719998100620227758
   PubMed Web of Science ®Google Scholar
• VisserMEWagenerGBakerBFMipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trialEur Heart J20123391142114922507979
   PubMed Web of Science ®Google Scholar
• VisserMEAkdimFTribbleDLEffect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemiaJ Lipid Res20105151057106220008831
   PubMed Web of Science ®Google Scholar
• BurnettJRHooperAJCommon and rare gene variants affecting plasma LDL cholesterolClin Biochem Rev2008291112618566665
   PubMedGoogle Scholar
• HortonJDCohenJCHobbsHHPCSK9: a convertase that coordinates LDL catabolismJ Lipid Res200950SupplS172S17719020338
   PubMed Web of Science ®Google Scholar
• SteinEADufourRGagneCA randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery diseaseEur Heart J20103189820402003
   PubMed Web of Science ®Google Scholar
• TardifJCMcGowanMCeskaRApolipoprotein B synthesis inhibition by mipomersen reduces low-density lipoprotein cholesterol when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemiaJ Am Coll Cardiol20115714E492
   Web of Science ®Google Scholar